Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential Lindsay FoxLewis S. Nelson Current Opinion 24 September 2019 Pages: 1147 - 1154
Novel IDH1-Targeted Glioma Therapies Georg Karpel-MasslerTrang T. T. NguyenMarkus D. Siegelin Leading Article 25 November 2019 Pages: 1155 - 1166
Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review Frank M. C. BesagMichael J. VaseyIan C. K. Wong Systematic Review 13 November 2019 Pages: 1167 - 1186
An Update on Vitamin D and Disease Activity in Multiple Sclerosis Joost SmoldersØivind TorkildsenTrygve Holmøy Review Article Open access 04 November 2019 Pages: 1187 - 1199
Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder Georgios SchoretsanitisJose de LeonMichael Paulzen Review Article 27 November 2019 Pages: 1201 - 1222
Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS) Amichai PerlmanMaor WanounouMordechai Muszkat Short Communication 04 November 2019 Pages: 1223 - 1228
Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis Maya GolanKarin Mausner-FainbergArnon Karni Original Research Article 12 November 2019 Pages: 1229 - 1237
